Position in BNTX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$331,258
-$50,837 QoQ
Shares Held
3,560
-17.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#169
of 282 holders
Holding Since
Jun 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BNTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. BNTX ranks #98 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in BNTX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $331,258 | 3,560 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $382,095 | 4,299 | Shares | Sole | 2026-05-08 | |
| 2024-09-30 | $372,700 | 3,138 | Shares | Sole | 2024-11-05 | |
| 2024-03-31 | $334,406 | 3,625 | Shares | Sole | 2024-05-03 | |
| 2023-06-30 | $594,694 | 5,510 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $631,445 | 5,069 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $663,071 | 4,414 | Shares | Sole | 2023-02-13 | |
| 2022-06-30 | $558,081 | 3,743 | Shares | Sole | 2022-08-09 | |
| 2021-12-31 | $316,320 | 1,227 | Shares | Sole | 2022-02-14 | |
| 2021-06-30 | $368,730 | 1,647 | Shares | Sole | 2021-08-05 | |
| No filing history on record for this holder in this stock. | ||||||